|
AU2007217529A1
|
|
Heterocyclic compounds and their use in the treatment of cardiovascular disease
|
|
GB0603376D0
|
|
Compounds and their use
|
|
GB0603374D0
|
|
Compounds and their use
|
|
GB0603378D0
|
|
Compounds and their use
|
|
WO2006059082A1
|
|
Oxidised lipids as reversal agents for boronic acid drugs
|
|
WO2006059083A1
|
|
Neutralising agents for boronic acid drugs
|
|
US2006084592A1
|
|
Peptide boronic acid inhibitors
|
|
US2005282757A1
|
|
Peptide boronic acid compounds useful in anticoagulation
|
|
GB0426264D0
|
|
Compounds
|
|
GB0426265D0
|
|
Compounds
|
|
US2005176651A1
|
|
Peptide boronic acids useful in making salts thereof
|
|
US2005119226A1
|
|
Methods for synthesizing organoboronic compounds and products thereof
|
|
GB0405279D0
|
|
Compounds
|
|
GB0405267D0
|
|
Compounds
|
|
GB0405194D0
|
|
Compounds
|
|
GB0405230D0
|
|
Compounds
|
|
GB0405280D0
|
|
Compounds
|
|
GB0405263D0
|
|
Compounds
|
|
GB0405248D0
|
|
Compounds
|
|
GB0405270D0
|
|
Compounds
|
